Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards cover 28,800 stock options at a $31.26 exercise price and 14,150 RSUs for ten new employees, vesting over four years.
AI-generated analysis. Not financial advice.
Positive
- Inducement grants cover 28,800 stock options and 14,150 RSUs for new hires
- Four-year vesting schedules support employee retention and long-term alignment
- Stock option exercise price set at $31.26, matching June 2, 2026 closing price
Negative
- Equity awards represent potential dilution of 42,950 Class A common shares
Key Figures
Market Reality Check
Peers on Argus
VERA gained 6.75% with elevated volume, while peers showed mixed moves: AUPH +4.67%, EWTX +3.45%, VRDN +0.18%, CDTX +0.03%, and ARDX -1.82%. No peers appeared in the momentum scanner, indicating a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Clinical development | Positive | -7.9% | FDA alignment on earlier ORIGIN Phase 3 eGFR analysis and timelines. |
| May 08 | Inducement grants | Neutral | +1.2% | Stock options and RSUs granted to new employees under inducement plan. |
| May 07 | Earnings update | Mixed | -1.9% | Q1 2026 loss, cash position, and Priority Review with set PDUFA date. |
| May 04 | Conference participation | Neutral | +0.9% | Planned presentation and investor meetings at a major health care conference. |
| Apr 10 | Inducement grants | Neutral | -3.0% | Large batch of stock options and RSUs to 89 new employees. |
Recent news has often seen muted or negative next-day price reactions, even on seemingly positive regulatory and clinical updates.
Over the last few months, Vera issued several operational and regulatory updates. An FDA alignment on an earlier ORIGIN Phase 3 eGFR analysis and a July 7, 2026 PDUFA date for atacicept were followed by a -7.9% move. Routine inducement grant announcements on April 8, 2026 and May 4, 2026 led to modest reactions between about -3% and
Market Pulse Summary
This announcement details equity inducement awards—stock options and RSUs—granted to new employees under Vera’s 2024 Inducement Plan at an exercise price of $31.26. Such grants are common for talent recruitment and align with Nasdaq Listing Rule 5635(c)(4). In context, Vera recently highlighted a July 7, 2026 PDUFA date for atacicept and reported a Q1 net loss of $121.0M with $596.8M in cash, so upcoming regulatory and clinical milestones remain the more material drivers to watch.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
restricted stock units financial
AI-generated analysis. Not financial advice.
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on June 2, 2026 has an exercise price per share equal to
About Vera Therapeutics
Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
